20th Feb 2018 13:15
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 12,482 (Deferred) | ||||
£0.0000 | 8,614 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 21,096 £0.0000 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£13.1563 | 5,868 (Deferred) | ||||
£13.1563 | 4,050 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 9,918 £13.1563 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor | |||
b) | Position/status | President, Global Manufacturing & Supply | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 9,142 (Deferred) | ||||
£0.0000 | 6,308 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 15,450 £0.0000 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||
a) | Name | Mr R Connor |
| |||
b) | Position/status | President, Global Manufacturing & Supply |
| |||
c) | Initial notification/ amendment | Initial Notification |
| |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||
a) | Name | GlaxoSmithKline plc |
| |||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
£13.1028 | 4,384 (Deferred) | |||||
£13.1200 | 3,026 (Matching) | |||||
d) | Aggregated information |
| ||||
Aggregated volume Price | 7,410 £13.1114 |
| ||||
e) | Date of the transaction | 2018-02-16 |
| |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr S Dingemans | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 17,435 (Deferred) | ||||
£0.0000 | 12,030 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 29,465 £0.0000 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||
a) | Name | Mr S Dingemans |
| |||
b) | Position/status | Chief Financial Officer |
| |||
c) | Initial notification/ amendment | Initial Notification |
| |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||
a) | Name | GlaxoSmithKline plc |
| |||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
£13.1236 | 8,360 (Deferred) | |||||
£13.1230 | 5,768 (Matching) | |||||
d) | Aggregated information |
| ||||
Aggregated volume Price | 14,128 £13.1233 |
| ||||
e) | Date of the transaction | 2018-02-16 |
| |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics and Compliance | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 6,402 (Deferred) | ||||
£0.0000 | 4,418 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 10,820 £0.0000 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||
a) | Name | Mr N Hirons |
| |||
b) | Position/status | SVP, Global Ethics and Compliance |
| |||
c) | Initial notification/ amendment | Initial Notification |
| |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||
a) | Name | GlaxoSmithKline plc |
| |||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
£13.1068 | 3,070 (Deferred) | |||||
£13.1118 | 2,120 (Matching) | |||||
d) | Aggregated information |
| ||||
Aggregated volume Price | 5,190 £13.1093 |
| ||||
e) | Date of the transaction | 2018-02-16 |
| |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 10,258 (Deferred) | ||||
£0.0000 | 7,078 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 17,336 £0.0000 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||
a) | Name | Mr D Redfern |
| |||
b) | Position/status | Chief Strategy Officer |
| |||
c) | Initial notification/ amendment | Initial Notification |
| |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||
a) | Name | GlaxoSmithKline plc |
| |||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
£13.1800 | 4,822 (Deferred) | |||||
£13.1800 | 3,328 (Matching) | |||||
d) | Aggregated information |
| ||||
Aggregated volume Price | 8,150 £13.1800 |
| ||||
e) | Date of the transaction | 2018-02-16 |
| |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms C Thomas | |||
b) | Position/status | SVP, Human Resources | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 13,805 (Deferred) | ||||
£0.0000 | 9,525 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 23,330 £0.0000 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms C Thomas | |||
b) | Position/status | SVP, Human Resources | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£13.1180 | 6,489 (Deferred) | ||||
£13.1180 | 4,478 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 10,967 £13.1180 | ||||
e) | Date of the transaction | 2018-02-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 4,689 (Deferred) | ||||
£0.0000 | 3,235 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 7,924 £0.0000 | ||||
e) | Date of the transaction | 2018-02-19 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£13.1240 | 2,204 (Deferred) | ||||
£13.1240 | 1,521 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 3,725 £13.1240 | ||||
e) | Date of the transaction | 2018-02-19 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr P Vallance | |||
b) | Position/status | Outgoing President, R&D | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£0.0000 | 20,322 (Deferred) | ||||
£0.0000 | 14,022 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 34,344 £0.0000 | ||||
e) | Date of the transaction | 2018-02-19 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr P Vallance | |||
b) | Position/status | Outgoing President, R&D | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares following the exercise of options on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£13.1760 | 20,322 (Deferred) | ||||
£13.1760 | 14,022 (Matching) | ||||
d) | Aggregated information | ||||
Aggregated volume Price | 34,344 £13.1180 | ||||
e) | Date of the transaction | 2018-02-19 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
Related Shares:
Glaxosmithkline